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Abstract: The etiology of Alzheimer’s disease (AD) remains unclear. The emerging view is that cerebrovascular dys-
function is a feature not only of cerebrovascular diseases, such as stroke, but also of neurodegenerative conditions, 
such as AD. In AD, there is impaired structure and function of cerebral blood vessels and cells in the neurovascular 
unit. These effects are mediated by vascular oxidative stress. Injury to the neurovascular unit alters cerebral blood 
flow regulation, depletes vascular reserves, disrupts the blood-brain barrier and reduces the brain’s repair capacity. 
Such injury can exacerbate the cognitive dysfunction exerted by incident ischemia and coexisting neurodegenera-
tion. This article summarises data regarding cardiovascular risk factors, vascular abnormalities and brain endo-
thelial damage in AD. In view of accumulating evidence of vascular pathology in AD, we also review the literature 
(MEDLINE, EMBASE) for clinical evidence of impaired endothelial function in AD. A total of 15 articles investigating 
endothelial dysfunction in AD were identified. 10 of these articles showed impaired endothelial function in AD 
patients. The current literature suggests endothelial dysfunction may be involved in the pathogenesis of AD. This 
aspect of AD pathology is particularly interesting in view of its potential for therapeutic intervention. Future research 
on endothelial function in AD should concentrate on population-based analysis and combine multiple methods to 
evaluate endothelial function.
Keywords: Alzheimer’s, dementia, endothelium, etiology, endothelial dysfunction, neurodegeneration, pathology, 
vascular disease 
Introduction
Alzheimer’s disease (AD) is a progressive, neu-
rodegenerative disorder characterised by a 
decline in cognitive function. Over 23.4 million 
people suffer from dementia today [1]. This fig-
ure is predicted to double every 20 years, 
reaching 81.1 million by 2040. According to 
numerous epidemiological studies AD is the 
most common subtype of dementia [2, 3]. 
However, whilst cerebrovascular disease is 
considered exclusion criterion for AD, lacunar 
infarcts have been observed in over 70% of AD 
patients’ suggesting that the differences 
between vascular dementia (VaD) and AD are 
not as definitive as initially postulated [4].
Despite thorough research, the pathogenesis 
of AD remains unclear. The most accepted 
hypothesis proposes that deposition of insolu-
ble amyloid β protein (Aβ) fragments causes the 
neurodegeneration in AD [5]. Aβ is thought to 
contribute to the accumulation of reactive 
oxygen species (ROS) resulting in oxidative 
stress, neuronal damage and cognitive decline. 
However, there is growing evidence from stud-
ies to suggest that vascular dysfunction plays a 
central role in the development of AD. Amyloid 
plaques and neurofibrillary tangles (NFTs) may 
be the result of hypoxia due to inadequate 
blood supply [6]. In vitro, Aβ has been shown to 
be toxic to both cerebral and peripheral endo-
thelium [7, 8]. It has been postulated that the 
neurotoxic effects of Aβ may impair normal 
endothelial function and cause endothelial-
dependent vasoconstriction [9, 10].
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Epidemiological studies, including the Honolulu-
Asia Study [11], Rotterdam Study [12, 13], 
EURODEM [14], and Kungsholmen Project [15] 
report several vascular risk factors (VRFs) asso-
ciated with AD-type dementia, all of which 
cause cerebral hypoperfusion. The association 
of vascular diseases with AD prevalence strong-
ly suggests that vascular mechanisms play a 
role in the development and/or progression of 
AD.
The endothelium is the monolayer of endothe-
lial cells lining the lumen of the vascular beds 
separating the vascular wall from the circula-
tion and the blood components with both meta-
bolic and mechanical roles. Endothelial dys-
function may be reversible so may represent a 
therapeutic target. 
Aims
In this paper, we review:
I) Evidence of vascular involvement in the 
pathogenesis of AD.
II) In vivo clinical studies investigating the rela-
tionship between AD and endothelial dysfunc- 
tion.
The neurovascular unit
Neurons and glial cells work in concert with 
endothelial cells (ECs) and smooth muscle cells 
to maintain homeostasis of the cerebral micro-
environment [16, 17]. Thus, the neurovascular 
unit maintains tight control of the chemical 
milieu of the brain by regulating local cerebral 
blood flow (CBF) and molecular transport 
across the blood brain barrier (BBB). Figure 1 
shows the structural arrangement of the neuro-
vascular unit.
Large cerebral arteries branch into smaller pial 
arteries that run along the surface of the brain 
across the subarachnoid space [18]. These are 
composed of an EC layer, a smooth muscle 
layer and an outer layer of adventitial cells. 
Penetrating intracerebral arteries are separat-
ed from the brain by the Virchow-Robin space 
[19]. As intracerebral arterioles penetrate 
deeper into the brain, this space disappears 
and the vascular basement membrane (VBM) 
comes into direct contact with the astrocytic 
end-feet. The VBM separates the endothelium 
from other cells of the neurovascular unit, 
including pericytes and astrocytes. 
Interestingly, cerebral ECs are not fenestrated 
but are interconnected by tight junctions form-
ing a continuous cellular structure, the BBB. 
The BBB prevents passive diffusion of solutes 
between the blood and brain intracellular fluid 
and limits uncontrolled entry of neurotoxic sub-
stances into the brain [20]. Specialised recep-
tors on the membrane of ECs initiate intracel-
lular signaling cascades in response to agonists 
that activate specific receptors, or changes in 
shear stress at the cell surface produced by 
changes in the rate of blood flow. Gap junctions 
permit crosstalk between adjacent ECs allow-
ing the transmission of intracellular responses. 
Once initiated, these cascades trigger the 
release of potent vasodilator substances such 
as nitric oxide (NO) and prostacyclin, and vaso-
constrictors, such as endothelin and endotheli-
um-derived constrictor factor [21-23]. At low 
concentrations, reactive oxygen species (ROS) 
function as vasodilators, however at high con-
centrations they cause vascular dysfunction 
[24].
Therefore, neurons, glia, and vascular cells 
compose a functional unit, which serves to 
maintain homeostasis of the cerebal microen-
vironment. Additionally, the neurovascular unit 
plays an important role in protection against 
cerebrovascular dysfunction and ischemia [25]. 
Current hypotheses on Alzheimer’s disease 
etiology
Much of the literature concerning theories of 
AD etiology favors one of two hypotheses - the 
‘amyloid cascade hypothesis’ (ACH) or the ‘vas-
cular hypothesis’. Whilst the ACH implicates the 
overproduction and deposition of Aβ fragments 
as the primary cause of AD [5, 26], the vascular 
hypothesis argues that cerebral hypoperfusion 
resulting from vascular disease and ageing 
leads to the neuronal death and cognitive 
dysfunction in AD (Figure 2).
The amyloid cascade hypothesis: Since the 
classification of presenile dementia by Alois 
Alzheimer in 1907, senile plaques and NFTs 
have been considered key pathological hall-
marks of AD [27]. The discovery of Aβ as the 
main constituent of senile plaques and the 
identification of gene mutations in amyloid pre-
cursor protein (APP), the presenilin 1 (PSEN1) 
gene and the presenilin 2 (PSEN2) gene caus-
ing Aβ accumulation and early onset familial AD 
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led to the ACH [28-30]. The ACH theorises that 
abnormal Aβ aggregation and deposition 
initiates the pathogenesis of AD and results in 
neuronal apoptosis, NFT formation and 
cognitive decline. Due to the similar phenotype 
between familial AD and late-onset AD, it was 
assumed that increases in Aβ deposition were 
the cause of all types of AD. Despite substantial 
evidence supporting senile plaque and NFT 
formation as the primary cause of AD, recent 
research has greeted this theory with more 
scepticism [31-35]. 
A number of observations are used to support 
the ACH. AD patients have amyloid plaques 
containing degenerating nerve endings; the 
plaque count in these patients is greater than 
in normal aging [36, 37]. Furthermore, Down’s 
syndrome patients invariably develop classical 
AD pathology by age 50. These individuals also 
overproduce Aβ from birth and amyloid plaques 
far precede NFTs and other AD lesions [38, 39]. 
APP over-expression mice initially develop dif-
criticised by many [31-35]. Senile plaques and 
NFTs may occur as a reactive response to neu-
rodegeneration rather than being its cause. In 
head trauma patients, similar pathological hall-
marks are seen as in AD patients in neuronal 
perikarya and in dystrophic neurites surround-
ing Aβ deposits [47]. Moreover, increased num-
bers of βAPP-immunoreactive neurons have 
been observed in the entorhinal cortex after 
head injury [48]. These findings suggest APP 
over-expression and amyloid deposition could 
occur as an acute-phase response to neuronal 
damage [49]. This concept of amyloid produc-
tion as a neurotrophic response is supported 
by the observations that APP shares structural 
similarities with the precursor for epidermal 
growth factor [50] and cerebellar Aβ-deposits 
contain acute phase proteins such as comple-
ment factors and α-anti-chymotrypsin [51]. 
Other evidence contradicting the ACH has also 
been reported. The degree of amyloid deposi-
tion in the brain does not correlate with the 
severity of cognitive dysfunction. In addition, 
Figure 1. The neurovascular unit. This diagram depicts a cerebral blood ves-
sel and surrounding brain parenchyma that comprise the neurovascular unit. 
The neurovascular unit encompasses cell-cell and cell-matrix interactions be-
tween component endothelial, glial, and neuronal cells. (Image adapted with 
permission from Iadecola 2004) [268].
fuse plaques, which develop 
into fibrillar plaques associat-
ed with damage to neurons 
and microglia [40]. Similarly, 
Aβ fibrils reproducibly dam-
age cultured neurons and 
activate brain microglia [41, 
42]. Blocking Aβ plaque for-
mation prevents this toxicity 
[43, 44]. A rare coding muta-
tion in the APP gene (A673T) 
which leads to approximately 
40% less APP cleavage actu-
ally protects against AD in the 
elderly [45]. Finally, Apoli- 
poprotein ε4 (APOE-ε4), a sig-
nificant genetic risk factor for 
AD, is associated with over-
production of amyloid in the 
brain before AD symptoms 
become evident. Each APO- 
E-ε4 allele lowers the age at 
onset in a dose-dependent 
fashion [46]. Thus, there is 
compelling evidence in favor 
of the ACH.
Due to recent evidence, how-
ever, the theory that senile 
plaque accumulation is the 
primary cause of neurode-
generation in AD has been 
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the brains of many individuals with normal cog-
nitive function have abundant senile plaques or 
NFTs [52, 53]. Transgenic mouse models over-
expressing APP show no neuronal loss in the 
CA1 region [54] and show cognitive dysfunction 
before Aβ deposition [55]. Furthermore, vacci-
nations against Aβ over 8 weeks do not improve 
cognition in mice transgenic for APP and prese-
nilin 1 [56]. Therefore, whilst there is evidence 
in support of the ACH, there are increasing 
questions about the validity of this theory.
The vascular hypothesis
The vascular hypothesis of AD suggests that 
pathology begins with cerebral hypoperfusion. 
This in turn leads to a crisis among glia and 
neurons, eventually culminating in neurodegen-
Hypertension: High blood pressure (BP) has 
been established as one of the strongest VRFs 
for AD [11, 14, 59, 60]. The Honolulu-Asia study 
followed up 3734 men and found a strong cor-
relation between midlife hypertension and AD 
[14]. This association was greatest in those not 
undergoing treatment with antihypertensive 
drugs. Moreover, neuroimaging and post-mor-
tem analysis of AD patients revealed that 
increased BP in midlife resulted in pathological 
changes in blood vessels, brain atrophy and an 
increase in senile Aβ plaques and NFTs in the 
neocortex and hippocampus [61]. Kivipelto et 
al. also found an association with midlife hyper-
tension and AD risk [59]. Recently, Rodrigue et 
al. found that hypertension interacts with the 
APOE-ε4 genotype to increase amyloid deposi-
Figure 2. Overview of the vascular and amyloid hypotheses of Alzheimer’s dis-
ease. The amyloid hypothesis proposes that overexpression of amyloid precur-
sor protein (APP) is the primary cause of Alzheimer’s disease (AD). Mutations 
in the presenilin 1, presenilin 2 and APP gene increase amyloid deposition and 
raise the risk of developing AD. Senile plaques are a key pathological feature 
of AD and in mouse models plaque formation is associated with neuronal dam-
age. The vascular hypothesis suggests vascular dysfunction associated with 
ageing is the primary trigger of AD. The prevalence of vascular risk factors is 
greater in the elderly population and vascular disease is strongly associated 
with risk of AD. Cerebral hypoperfusion resulting from impaired vasoregulation 
in vascular disorders causes a neuroglial energy crisis resulting in cognitive. 
Vascular dysfunction promotes the conversion from mild cognitive impairment 
to AD.
eration and cognitive impair-
ment. In addition, interac-
tions between vascular dys- 
function and increased amy-
loid production that facili-
tate the pathogenesis of AD 
will be discussed.
Vascular disease and Al-
zheimer’s disease
Several vascular diseases 
are associated with an 
increased risk of AD, all of 
which induce cerebral hypo-
perfusion [11, 13, 15]. 
Recently, Kaffashian et al. 
found that Framingham gen-
eral cardiovascular disease 
(CVD) and stroke risk scores 
correlate with cognitive dec- 
line in late middle age and 
may be effective for assess-
ing risk of cognitive dysfunc-
tion and targeting modifi-
able risk factors [57]. 
Furthermore, Li et al. 
showed that VRFs promote 
conversion from mild cogni-
tive impairment to AD [58]. 
In the same study, treat-
ment of VRFs reduced the 
risk of incident AD. Inte- 
raction between AD pathol-
ogy and VRFs may aggra-
vate perfusion abnormalities 
in AD (Figure 3).
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tion in cognitively healthy middle-aged and 
older adults [62]. Furthermore, increased pulse 
pressure was strongly associated with 
increased mean cortical amyloid level for sub-
jects with at least one ε4 allele. These findings 
suggest that hypertension greatly exacerbates 
neuropathological and cognitive brain changes 
in patients susceptible to AD.
Angiotensin II (Ang II) is an important vasoac-
tive peptide hormone associated with hyper-
tension. Angiotensin I (Ang I) is converted to 
Ang II through removal of two C-terminal resi-
dues by angiotensin-converting enzyme (ACE), 
causing vasoconstriction and increased BF. 
Ang II also activates NADPH oxidase (NOX), 
leading to increased ROS production and oxida-
tive stress [63, 64].
Several studies have reported increases in ACE 
activity in patients with AD. Increased binding 
of radioactively labeled ACE-I to ACE in the tem-
poral cortex and elevated neuronal and peri-
operfusion through impairment of normal vas-
cular regulation or atherosclerosis. An increase 
in systemic BP can result in BBB dysfunction in 
cerebral microvasculature, which further dam-
ages subcortical vessels [72]. In addition, this 
causes impairment of solute transport to the 
brain and a decrease in glucose delivery results 
in expression leading to an increase in amyloid 
fibrillogenesis [73]. Therefore, hypertension 
probably increases the risk of AD by disrupting 
BBB transport, increasing Ang II production, 
damaging the endothelium and causing pro-
duction of amyloid and free radicals.
Obesity: Epidemiological research has shown 
obesity in midlife is a strong risk factor for AD, 
however this relationship may not be present 
as ageing progresses further [74, 75]. Singh-
Manoux et al. analysed 6401 adults aged 
39-63 years and found that increased BP and 
other metabolic factors resulting from excess 
body weight causes middle-aged and older 
adults to experience a rapid decline in cognitive 
Figure 3. Interaction between vascular disease and AD pathology. Arrows 
indicate how cerebrovascular factors influence amyloid processing. Hypoxia 
resulting from vascular disease (e.g atherosclerosis) causes increased ex-
pression of hypoxia-inducible factor (HIF)-1α. HIF-1α binds to the hypoxia-
responsive element on amyloid cleaving enzyme BACE1. The resulting upreg-
ulation of BACE1 mRNA expression increases the production of Aβ fragments. 
Hypoperfusion resulting from vascular disease and old age further increases 
BACE1 activity. In addition, hypoperfusion may contribute to oxygen deficiency 
and cause a neuroglial energy crisis, further ameliorating amyloid plaque pro-
duction, CAA and ischaemia. CAA = Cerebral amyloid angiopathy, BACE1 = 
beta secretase 1, sAPP = secreted form of beta-APP, APP = amyloid precur-
sor protein, Aβ = beta amyloid peptide. Image adapted with permission from 
Kalaria et al. [59].
vascular ACE immunoreactiv-
ity has been observed in AD 
patients post-mortem [65, 
66]. Furthermore, Miners et 
al. found the strength of the 
increase in perivascular ACE 
immunoreactivity correlated 
not only with the level of cere-
bral amyloid angiopathy (CAA) 
but also with AD severity [67]. 
Not only does ACE catalyse 
the production of Ang II, it 
also cleaves Aβ [68]. The 
cleavage Aβ of by ACE may 
contribute to pathological Aβ 
misfolding. Further evidence 
for the role of Ang II and ACE 
in AD pathogenesis comes 
from clinical trials of ACE 
inhibitors (ACE-Is) and angio-
tensin receptor blockers (AR- 
Bs), which lower the risk of 
developing AD, alleviate cog-
nitive decline and decrease 
the load of amyloid plaques 
in the brain [69-71].
Long-lasting increases in BP 
may worsen the risk of AD by 
inducing small vessel dis-
ease, structural white matter 
alterations and cerebral hyp- 
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skills [76]. Participants who were both obese 
and metabolically abnormal showed a 22.5% 
faster decline in memory and thinking skills 
than control subjects. The increase in preva-
lence of AD in obese individuals is, in part, due 
to insulin resistance. Around 80% of individuals 
with obesity also suffer from insulin resistance 
[77]. However, many other risk factors associ-
ated with obesity also increase the risk of 
developing AD.
Plasma free fatty acid (FFA) levels are increased 
in most obese individuals [78]. Moreover, obe-
sity causes inhibition of the enzyme metallo-
proteinase, which is associated with amyloid 
clearance [79, 80]. In cultured vascular cells, 
high FFAs stimulate ROS production through 
protein kinase C-dependent activation of NOX 
[81]. These findings suggest that obesity 
increases oxidative stress and amyloid accu-
mulation in the vasculature which may increase 
the risk of dementia. Kalmijn et al. found 
increased FFAs caused increased tau and amy-
loid expression [82]. Furthermore, elevated 
FFAs initiate the release of compounds such as 
Ang II and TNF-α, which may exacerbate the 
development of AD [83].
The relationship between obesity, atherosclero-
sis and hypercholesterolemia is well estab-
lished [84, 85]. Hofman et al. found a 3-fold 
increase in risk of developing AD or VaD in 
patients with atherosclerosis [13]. Athe- 
rosclerosis in carotid arteries produced the 
strongest risk of developing dementia. In a 6 
year follow-up study of elderly individuals with 
arterial stiffness and atherosclerosis, high 
pulse pressure (low diastolic and high systolic) 
was associated with AD and VaD [86]. These 
findings suggest aortic compliance and stroke 
volume play important roles in AD pathogene-
sis. Postmortem grading of Circle of Willis ath-
erosclerotic lesions shows that atherosclerosis 
is more severe in cases with AD [4, 87]. 
Unsurprisingly, atherosclerosis in the Circle of 
Willis is positively associated with the forma-
tion of neuritic plaques and NFTs [88]. 
Endothelial and perivascular damage are com-
mon features of atherosclerosis, which may 
result in diminished blood flow and inhibition of 
EDNO [89]. Accordingly, dysregulation of EDNO 
resulting from chronic brain hypoperfusion 
causes spatial memory loss and Aβ40 deposi-
tion in the rat hippocampus [90]. Due the slow 
onset and progression of atherosclerosis, it is 
probable that the occlusion of coronary arteries 
prior to cognitive decline precedes AD symp-
toms. These results may explain the current 
findings on human cognitive dysfunction and 
brain hypoperfusion [91]. In patients with carot-
id artery stenosis who have undergone a carot-
id endarterectomy and shown no sign of micro-
embolism following surgery cognition is often 
improved. If however, microembolic events are 
identified or brain perfusion is not restored, 
cognition does not tend to improve [92]. If the 
theory that vessel occlusion precedes cognitive 
dysfunction is correct, prevention of athero-
sclerosis may significantly lessen AD preva- 
lence. 
Elevated cholesterol levels also seem to con-
tribute to AD pathology. In vitro, high cholester-
ol leads to overproduction of Aβ [93]. Aβ was 
found to inhibit cholesterol trafficking and alter 
cholesterol homeostasis leading to neurode-
generation and the onset of AD pathology, sug-
gesting Aβ has a role in control of cholesterol 
transport. In addition, cholesterol secosterol 
aldehydes initiate Schiffs base-formation 
resulting in enhanced amyloidogenesis [94, 
95]. Thus, obesity may contribute to AD via a 
number of mechanisms including increased 
cholesterol, atherosclerotic occlusion of cere-
bral blood vessels and insulin resistance. 
Diabetes mellitus: A number of population-
based studies have found an association 
between diabetes mellitus and AD with an inci-
dence of AD as high as 2-5 times higher in 
patients with type-II diabetes [12, 96-98]. Both 
diabetes and AD are associated with localised 
amyloid accumulation and both increase in 
prevalence during ageing. Whilst elevated 
peripheral insulin levels initially result in 
increased brain insulin, prolonged hyperinsu-
linemia reduces brain insulin levels via down-
regulation of BBB insulin receptors and reduced 
insulin transport into the brain [99, 100]. 
Insulin receptors are expressed in high concen-
trations in areas of the brain associated with 
learning and memory such as the hippocampus 
and limbic system, which may explain the cor-
relation between hyperinsulinemia and cogni-
tive decline [101]. Hyperinsulinemia initiates 
central inflammation and Aβ production in 
healthy individuals [102]. In mice with strepto-
zotocin-induced diabetes, impaired insulin-sig-
naling results in tau hyperphosphorylation and 
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elevated Aβ [103]. Furthermore, rat models of 
spontaneous diabetes elicit pathological 
changes similar to that observed in AD [104].
Insulin resistance is a key pathological feature 
of diabetes and there is growing evidence to 
suggest a link between insulin resistance and 
AD. Extensive abnormalities in insulin and insu-
lin-like growth factor type I and II signalling 
mechanisms have been observed in brains 
with AD, with markedly reduced expression of 
genes encoding insulin [105]. Hence, insulin 
resistance in AD has been referred to as ‘type-
3 diabetes’. Insulin resistance is also associat-
ed with increased oxidative stress, elevated 
cortisol and mitochondrial dysfunction, which 
may contribute to cognitive dysfunction [106]. 
So, diabetes probably increases the risk of AD 
by increasing senile plaque and NFT produc-
tion, inducing an inflammatory response, 
increasing free radical production and causing 
disruption of nutrient transport in the BBB.
Cerebrovascular disease (stroke): Numerous 
studies have found an association between 
stroke and AD [4, 107, 108]. Lesions in the 
white matter surrounding cerebral ventricles 
closely resembling ischaemic infarcts have 
been observed in neuropathological studies of 
AD [109]. Microvascular lesions are a common 
pathological feature of AD, with similar num-
bers of lesions being present as there are NFTs 
and amyloid plaques [110]. Moreover, subcorti-
cal infarcts co-exist with AD pathology and 
increase the risk of developing dementia 4-fold 
[111]. 
It has been postulated that cerebrovascular 
damage (e.g. microinfarcts) precedes the devel-
opment of AD symptoms. Patients with AD have 
more pronounced atherosclerotic lesions in the 
Circle of Willis than age-matched controls and it 
has been suggested that ischaemic stroke is 
the main cause of AD in some individuals [87]. 
Also, AD is more damaging in the presence of 
cerebral infarction and autopsy studies show 
around 70% of patients diagnosed with AD 
have evidence of coexistent cerebrovascular 
disease [4, 107]. A strong correlation between 
infarcts and AD has been observed, with micro-
infarcts restricted to watershed cortical zones 
[112]. Interestingly, CAA was an important risk 
factor for watershed microinfarcts, suggesting 
perturbed hemodynamic factors (e.g. decre- 
ased BP) play a role in the genesis of cortical 
watershed microinfarcts, which may further 
aggravate degeneration and worsen dementia. 
CAA occurs in over 80% of patients with AD and 
only around 10% of control subjects. The high 
incidence of CAA in AD patients suggests it may 
contribute to the development of AD. CAA is 
associated with damage to smooth muscle in 
the cerebral vasculature and reduced amyloid 
clearance [113]. Pathological amyloid accumu-
lation may have a role in the development of 
haemorrhagic stroke in AD [114].
In a large population-based study silent stroke 
doubled the risk of AD in patients aged 60 to 
90 years [115]. Lacunar infarcts are small sub-
cortical infarcts that result from occlusion of a 
single perforating artery [116]. In individuals 
suffering from silent subcortical lacunar 
infarcts, cognitive decline correlates with 
decreased cerebral glucose metabolism and it 
was found that hypometabolism was a better 
indicator of cognitive dysfunction than struc-
tural changes (e.g. hippocampal atrophy). In 
conclusion, ischemia, microinfarcts and lesions 
in AD may provoke stroke triggering the devel-
opment or progression of AD by reducing blood 
flow and invoking amyloid overproduction in the 
brain. It is plausible that a reduction in CBF 
resulting from stroke facilitates the conversion 
of preclinical AD to AD. Using effective interven-
tion strategies to prevent VRFs may reduce the 
risk of AD.
Morphological changes of the cerebral micro-
vasculature in Alzheimer’s disease
There is increasing recognition that structural 
changes in cerebral blood vessels contribute to 
the development and progression of AD. 
Although the presence of cerebrovascular dis-
ease is considered exclusion criterion for AD, 
cerebral capillary degeneration has been found 
in almost all AD brains examined postmortem 
and in cortical biopsy material from pathologi-
cally confirmed AD [117, 118]. Morphological 
changes in cerebral microvasculature (capillary 
atrophy, kinking, focal constriction, VBM thick-
ening) have been found to relate to areas of Aβ 
deposition [119]. The most notable change 
appears to be thickening of the VBM. The three 
central components of the VBM are collagen 
type 1V, laminin, and heparan sulfate proteogly-
can (HSPG). Laminin and HSPG are both locat-
ed at the endothelial (lamina rara interna) and 
the astrocytic (lamina rara externa) VBM sur-
faces [120, 121]. Both have a role in cell adhe-
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sion and attachment and are potent neurite-
promoting factors [122, 123]. HSPG is 
negatively charged allowing it to filter anionic 
and neutral proteins. Charge is crucial in 
homeostasis of the renal glomerular barrier 
and may be important for the BBB as well [124, 
125]. The functional role of the VBM in the 
maintenance of the BBB is not well established, 
however it has been postulated that blocked 
anionic sites could result in disrupted BBB 
function [126]. Modification of the lamina rara 
interna could also result in altered attachment 
and adhesion of the EC. Pathology of the VBM 
could be associated with impaired solute trans-
port, resulting in leakage of neurotoxic plasma 
substances or circulating APP into the brain 
[127, 128]. Therefore, VBM pathology In AD 
may alter the ECs ability to maintain the BBB.
Vascular insufficiency and neurodegeneration
The damaging effect of VRFs and Aβ on 
cognition suggests a link between ischemia 
and neurodegeneration. In AD, CBF is reduced 
and functional hyperaemia is impaired [129, 
130]. Furthermore, studies indicate that chang-
es in CBF are a powerful predictor of AD [131, 
Conversely, it has been postulated that the 
toxic effects of Aβ on cerebral blood vessels 
may induce cerebral hypoperfusion and 
increase vulnerability to ischemic damage. In 
APP over-expression mice focal cerebral isch-
emia produces more severe infarcts than con-
trols, implicating Aβ as a cause for 
cerebrovascular dysfunction [141]. Similarly, a 
higher incidence of cerebrovascular lesions is 
seen in individuals with AD post-mortem [142]. 
Paradoxically, VRFs can increase vulnerability 
to AD without affecting neurodegenerative 
pathology. Despite a two-fold increase in risk of 
developing AD in diabetics, no increase in amy-
loid plaques or tau NFTs is observed. In fact, a 
higher number of microinfarcts have been iden-
tified in these individuals suggesting that micro-
vascular lesions may augment the effects of 
the neurodegenerative pathology in AD [143]. 
Since amyloid plaques appear to promote isch-
emia and vice versa, it is plausible that there is 
a synergistic relationship between the amy-
loidogenic and vascular features of AD pathol-
ogy (Figure 4).
The research on NFTs and vascular insufficien-
cy is far less conclusive. Elderly patients with 
Figure 4. Proposed synergistic relationship between vascular insufficiency 
and Alzheimer’s disease (Iadecola, 2010 [269]). Vascular insufficiency result-
ing from vascular risk factors (e.g vascular dementia) can promote β-amyloid 
(Aβ) production by increasing amyloid cleaving enzyme β secretase-1 and 
reducing Aβ clearance. Overexpression of amyloid precursor protein in Al-
zheimer’s disease leads to the formation of senile Aβ plaques, which may 
induce ROS-mediated vascular damage and compromised vasoregulation. 
Thus, vascular insufficiency and β-amyloid production may interact via a posi-
tive feedback mechanism exacerbating cognitive decline and increasing the 
risk of dementia.
132]. Amyloid plaques and 
NFTs often coexist with vas-
cular pathology in individuals 
with dementia [133]. Isc- 
haemic conditions may trig-
ger Aβ accumulation by ele-
vating AβPP/β-secretase ex- 
pression and facilitating 
amyloidogenic cleavage lea- 
ding to increased levels of 
toxic Aβ. In animal models, 
amyloid deposition is inc- 
reased in the cortex in 
response to ischemia [134, 
135] and a similar process is 
thought to occur in humans 
[136]. Indeed, accumulation 
of both Aβ1-40 and Aβ1-42 has 
been shown to increase dra-
matically and consistently 
after cerebral ischemia [137- 
139]. It is therefore unsur-
prising that individuals with 
cerebrovascular insufficien-
cy or VaD have increased lev-
els of Aβ and senile plaques 
[140].
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hypertension have increased hippocampal 
NFTs in comparison to control subjects [144]. 
Furthermore, focal cerebral ischemia enhances 
tau phosphorylation in rodent stroke models 
[145]. However, transient hypoperfusion mark-
edly decreases total tau levels in triple trans-
genic mice expressing amyloid plaques and 
NFTs. In summary, there is evidence to suggest 
ischemia contributes to accumulation of Aβ by 
reducing its degradation and promoting its syn-
thesis whereas the extent to which ischemia 
regulates tau phosphorylation remains elusive.
Another important question being raised by 
researchers in this area is whether or not vas-
cular dysfunction and ischemia aggravate cog-
nitive decline in AD. The presence of vascular 
lesions contributes significantly to the severity 
of cognitive impairment in AD [146]. Moreover, 
cerebrovascular disease has a greater capacity 
to influence cognitive performance at early 
stages of AD than at more advanced stages of 
the disease [147] VRFs and lesions also accel-
erate the progression of cognitive decline in AD 
[148]. Finally, a study assessing cerebrovascu-
lar reactivity to hypercapnia with transcranial 
Doppler ultrasonography, a measure of cere-
brovascular function, found an association 
between impaired cerebral microvessels func-
tionality and cognitive decline in patients with 
AD [149]. In conclusion, there is considerable 
evidence to suggest that vascular dysfunction 
is linked to cognitive degeneration in AD. 
Vascular dysfunction and oxidative stress in 
Alzheimer’s disease
Vascular oxidative stress induced by elevated 
Aβ has emerged as a key pathogenic factor in 
cerebrovascular dysfunction [24, 150]. ROS are 
highly reactive molecules that often have 
unpaired electrons in their outer orbital. 
Increased production of free radicals and ROS 
can disrupt cell membranes and consequently 
impair cell function (Figure 5).
Vascular oxidative stress has been observed in 
APP over-expression transgenic mice, without 
any evidence of oxidative stress in other areas 
of the brain [151]. In the same transgenic mod-
Figure 5. Membrane-related amyloid fibrillogenesis and oxidative stress in the pathogenesis of Alzheimer’s disease. 
Ageing is associated with reduced tissue antioxidant levels, oxidative lipid damage and enhanced Aβ protein aggre-
gation. These changes are even more pronounced in Alzheimer’s disease. Thiol-mediated antioxidant activity is ab-
sent in Apolipoprotein E4 alleles which may allow excess oxidative damage to the lipids in lipoprotein particles. Aβ 
proteins have a pro-oxidant activity towards the polyunsaturated lipids of cell membranes. Lipid oxidation products 
may exert direct neurotoxicity or induce structural changes in the His residues of Aβ42, enhancing its membrane 
affinity. Furthermore, these products may facilitate the oligomerization of Aβ40 and promote fibrillogenesis. Highly 
reactive oxygen species may be produced as a result of trauma induced-inflammation or fibrillogenesis. Inflam-
mation may also occur in the presence of vascular disease (e.g atherosclerosis). During these processes, Aβ may 
form neurotoxic pores or channels in endothelial or neuronal membranes. Image adapted from Axelsen et al. [270].
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els, antioxidant therapy or over-expression of 
free radical scavenger superoxide dismutase 
reverses Aβ-mediated cerebrovascular dys-
function, including alterations in both function-
al hyperemia and endothelial-dependent vaso-
dilatation [152, 153]. Furthermore, substitution 
of methionine 35 with norleucine, a mutation 
that blocks the ability of Aβ to generate ROS, 
abolished Aβ1-40 vasoactivity suggesting that 
Aβ1-40 plays a role in the cerebrovascular altera-
tions observed in AD [154]. 
Experimental studies suggest that free radicals 
produced by NOX are responsible for the cere-
brovascular alterations induced by Aβ [155, 
156]. ROS produced by NOX contribute to CVDs 
associated with vascular oxidative stress 
including atherosclerosis, hyperhomocystein-
aemia and hypertension.
The involvement NOX and oxidative stress in AD 
is illustrated by an increase in NOX levels or 
activity in mild cognitively impaired and AD 
brain tissues [157, 158]. Moreover, Aβ induces 
mitochondrial dysfunction and oxidative stress 
in astrocytes and microglia through activation 
of NOX [156, 159].
Accumulating evidence suggests ROS impair 
normal vascular function. In animal models of 
various disease conditions ROS cause endo-
thelial dysfunction [160]. Reaction of ROS 
superoxide with NO- generates peroxynitrite, a 
potentially deleterious oxidant. Several altera-
tions in the function of endothelium are initiat-
ed by this reaction. The most established is 
endothelium-dependent vasorelaxation, which 
is impaired by a loss of NO- bioactivity in the 
vessel wall [161, 162]. ROS and peroxynitrite 
can also trigger oxidative damage to proteins 
and nucleic acids, including strand breaks in 
DNA and base/nucleotide modifications, par-
ticularly in sequences with a higher number of 
guanosine bases [163]. In addition, peroxyni-
trite formation inhibits the activity of prostacy-
clin synthase, reducing the ability of blood ves-
sels to dilate [164]. Tetrahydrobiopterin, a 
critical cofactor for the NO synthases, is a cru-
cial target for oxidation by peroxynitrite and in 
its absence these enzymes become uncoupled, 
producing ROS rather than NO and causing fur-
ther oxidative stress [165]. Therefore, ROS-
mediated vascular dysfunction is caused by 
decreased availability of NO and changes in 
enzymes essential for normal vascular 
function.
Aβ also contributes to neurovascular dysfunc-
tion through other mechanisms. In addition to 
causing endothelial dysfunction, Aβ can dam-
age other components of the neurovascular 
unit. Aβ causes damage and apoptosis of glia 
and neurons, which may attenuate CBF 
response to stimuli [166, 167]. Moreover, intra-
cortical microvessels and NO containing neu-
rons in AD are deprived of a cholinergic neuro-
genic control, which probably leads to a 
compromised ability to adjust cortical perfu-
sion in response to neuronal activation during 
functional tasks related to cognition [168]. 
Thus, Aβ-mediated damage to neurovascular 
coupling is not solely a result of vascular dys-
function but also involves damage to neurons 
and glia.
Pharmacotherapy
Current drugs associated with a modest reduc-
tion in AD symptoms such as cholinesterase 
inhibitors also exert beneficial effects on cere-
bral perfusion [169]. Although these drugs 
decrease synaptic breakdown of acetylcholine 
(ACh), it is possible that their effect on CBF also 
plays a role in their protective action. 
Considering the vast amount of evidence sug-
gesting cerebral hypoperfusion is important in 
AD development, drug trials for statins, non-
steroidal inflammatory drugs (NSAIDs) and anti-
hypertensives in the prevention or treatment of 
AD were initially promising.
However, many potential treatments have not 
been as efficacious as expected. Statins are a 
class of drugs that inhibit 3-hydroxy-3-methylgl-
utaryl coenzyme A (HMG-CoA) reductase. HMG-
CoA reductase is the rate-limiting enzyme in 
the cellular cascade of cholesterol biosynthe-
sis. Statins may also reduce Aβ production and 
inhibit the activation of Rac1, which is critically 
involved in the activation of NOX [170]. In addi-
tion, statins downregulate AT-1 receptor gene 
expression mediated by destabilization of AT-1 
messenger ribonucleic acid. 
Due to the possible link between elevated cho-
lesterol and dementia studies have been car-
ried out to test the effect of statins in AD 
patients. Despite the fact that observational 
studies suggest statin therapy exerts a 
beneficial effect between normal cognitive per-
formance and profound dementia [171], results 
from randomised control trials have been dis-
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appointing in both prevention [172, 173] and 
treatment [174, 175] of AD. 
The prevalence of AD is decreased in patients 
with rheumatoid arthritis, suggesting NSAIDs 
may exert a protective effect against AD. 
Different NSAIDs inhibit COX isoforms, and the 
expression levels of COX-1 and COX-2 change in 
the different stages of AD pathology [176]. 
Furthermore, COX-1 is heavily expressed in 
microglia, which are associated with fibrillar Aβ 
deposits and some NSAIDs inhibit amyloid pro-
duction via Y-secretase [177]. Indeed, longitu-
dinal observation studies report a reduction in 
AD symptoms in patients taking NSAIDs [178, 
179]. Nevertheless, clinical trials found no 
association between NSAID treatment and cog-
nitive impairment. It is possible that trials were 
not sustained for a long enough period to yield 
effective results. More than 2 years of consis-
tent NSAID treatment is likely to be required in 
order to decrease the risk of AD [179]. Moreover 
initiation of treatment should occur several 
years before the onset of AD [180]. However, it 
is still unclear whether or not inflammatory 
mechanisms are invoking damage in AD or 
whether they are present to remove the debris 
from other more important pathological 
processes. 
Recent evidence suggests antihypertensive 
medication may be protective against AD [69-
71, 181]. In particular, drugs affecting the pro-
duction of Ang II may have neuroprotective 
effects. A UK case-control study found that 
fewer patients prescribed ARBs and ACE-
inhibitors went on to develop probable AD 
[182].
Patients taking ARBs had the lowest risk of 
developing AD, which may have been due to a 
lack of ACE-mediated amyloid degradation 
when taking these drugs [183]. In addition, 
treatment with ARBs is associated with less 
AD-related pathology on autopsy evaluations 
[184]. Large randomised clinical trials are war-
ranted to further investigate the relationship 
between antihypertensive drugs and dementia. 
In conclusion, although there is a relationship 
between VRFs and AD, drug trials have been 
less successful than anticipated. These find-
ings suggest that the ability of pharmacological 
intervention in reversing AD pathology is 
limited. 
Endothelial damage and repair in Alzheimer’s 
disease
Endothelial damage and Amyloid-β: Numerous 
factors may contribute to endothelial dysfunc-
tion in AD. ECs in the cerebral vasculature may 
contribute to the formation of amyloid deposits 
surrounding the cerebral blood vessels. 
Cerebral ECs express APP-cleaving secretases, 
which may cleave platelet-retained Aβ into frag-
ments leading to increased cerebrovascular 
amyloid deposition [185-187]. Therefore, brain 
ECs in AD may produce Aβ causing increased 
amyloid accumulation and potentially enhanc-
ing CAA.
Wu et al. measured gene levels in brain ECs iso-
lated from frontal cortex autopsies in patients 
with late stage AD, age-matched controls and 
healthy young adults [188]. Interestingly, the 
expression of MEOX2, a homeobox gene that is 
upregulated during vascular differentiation, is 
significantly reduced in late-stage AD and is 
required for optimal clearance of Aβ in mice 
brains. Restoring MEOX2 gene expression in 
brain ECs from individuals with AD enhanced 
angiogenesis, transcriptionally suppressed 
AFX1 forkhead transcription factor-mediated 
apoptosis and increased the levels of both a 
major Aβ clearance receptor at the BBB, the 
low-density lipoprotein receptor- related protein 
1 (LRP), and its receptor-associated protein 
(RAP). They found that in MEOX2 +/- mice, there 
was a decrease in CBF and capillary length, 
and that vessels from these mice had an 
impaired angiogenic response to hypoxia. 
These findings suggest that MEOX2 may be 
playing a role in neurovascular dysfunction and 
other important changes in the AD brain that 
could contribute to cognitive decline. Thus, 
MEOX2 could represent a potential new thera-
peutic target for AD patients.
Aβ has been found to be toxic to cerebral ECs in 
vitro by causing damage to nuclear and mito-
chondrial DNA and activation of caspase-8 and 
caspase-3, which have essential roles in apop-
tosis [189]. In the same study, Aβ-mediated 
damage to ECs was inhibited by zVAD-fmk, a 
broad-spectrum caspase inhibitor or N -acetyl-
cysteine, an antioxidant. Numerous other stud-
ies have shown the toxic effects of Aβ on ECs, 
implicating Aβ as the primary cause for 
impairment of NO production and mitochondrial 
dysfunction [190, 191]. Interestingly, Aβ 
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appears to be dependent on EC state [192]. 
Moreover, Aβ1-42 induces EC degeneration by 
raising intracellular calcium via calcium perme-
able Aβ channels [193]. These findings suggest 
a number of signaling pathways could be 
involved in EC dysfunction in AD. Moreover, dis-
ruption of normal endothelial function may pre-
cede Aβ deposition suggesting that endothelial 
dysfunction may play a central role in AD 
pathogenesis.
Both TNF-α and Aβ are over-expressed in AD. It 
is possible that TNF-α and Aβ induced altera-
tions in the ASK1-JNK/p38 apoptotic signalling 
pathways are responsible for EC apoptosis and 
damage [194, 195]. There is evidence to sug-
gest protein phosphatase 2A is required for 
ASK1 activation in ECs [195]. During 
Aβ-mediated EC apoptosis activation of sphin-
gomyelinase releases ceramide which in turn 
activates PP2A. Ceramide is involved in the 
expression of NADPH-oxidase in ECs and may 
contribute to ROS-induced damage to ECs 
[196]. Thus, TNF-α and amyloid induced chang-
es in apoptotic signalling may contribute to EC 
damage and vascular dysregulation in AD.
Regenerative capacity of brain endothelial 
cells: The process of vasculogenesis was ini-
tially thought only to occur during embryonic 
development, but not in postnatal life [197]. 
However, there is increasing evidence to sug-
gest that bone derived endothelial progenitor 
cells (EPCs) contribute to neovascularization 
and neoendothelialization and differentiate 
into ECs in response to injury [198]. In patients 
with AD, decreased levels of circulating EPCs 
have been recorded [199]. Levels of EPCs have 
been suggested to correlate with endothelial 
dysfunction in AD [200]. Moreover, AD-asso- 
ciated peptide Aβ40 blocks endothelial and vas-
cular regeneration and initiates autophagy 
[201]. A possible explanation for the inhibitory 
effect of Aβ on endothelial repair was provided 
by the observation that Aβ blocks vascular 
endothelial growth receptor (VEGR)-2 [202]. 
Therefore, the regenerative capacity of ECs 
may be compromised in AD, perhaps due to the 
inhibitory actions of Aβ. Since endothelial dys-
function may contribute to Aβ deposition, it is 
possible that endothelial damage in AD results 
in a positive feedback loop whereby more Aβ is 
produced and further aggravates endothelial 
injury and impairs repair.
The injection of EPCs to induce neovasculariza-
tion and restore CBF may be a promising treat-
ment opportunity for AD. Indeed, neovascular-
ization can be successfully stimulated by 
incorporating EPCs into ischaemic sites in ani-
mal models [203] and human myocytes [204].
Review of clinical evidence investigating the 
relationship between endothelial dysfunction 
and Alzheimer’s disease
Considering the wide range of research favor-
ing a vascular cause for AD discussed in the 
first section of this review, we believe an analy-
sis of the in vivo evidence of endothelial dys-
function in AD is timely. In this section, we 
review the literature investigating the relation-
ship between endothelial dysfunction and AD 
using specific search terms and selection 
criteria.
In vivo assessment of endothelial function
Despite the evidence supporting the role of 
endothelial dysfunction in AD, its routine mea-
surement in the clinical setting is challenging. 
However, due to recent advances in techniques 
to assess endothelial dysfunction it may now 
be possible to determine the extent to which 
vascular impairment correlates with AD. In 
recent years, a number of non-invasive tech-
niques have been used to assess endothelial 
function and morphology as an easier and safer 
alternative to direct assessment of the coro-
nary arteries [205]. Endothelial responses in 
peripheral vessels correlate well with coronary 
artery responses [206].
The capacity of blood vessels to respond to 
mechanical and pharmacological stimuli in the 
lumen denotes the ability to self-regulate tone 
and to adjust blood flow and distribution in 
response to changes in the local environment. 
NO is probably the most important vasoactive 
substance produced by the endothelium. 
A number of pharmacological (e.g. bradykinin) 
and mechanical (e.g. sheer stress) stimuli lead 
to the production of nitric oxide (NO) [207]. 
Endothelium derived NO (EDNO) is synthesised 
from the amino acid L-arginine by the endothe-
lial isoform of NO synthase (eNOS), yielding 
L-citrulline as a byproduct [208]. Specialised 
calcium-mediated potassium ion channels in 
the EC membrane open in response to sheer 
stress [209-211]. Opening K+ channels hyper-
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polarize the EC, increasing influx of calcium 
ions (Ca+). Calcium activates eNOS which catal-
yses the production of endothelial NO [212, 
213]. NO diffuses across the endothelial cell 
membrane and enters the vascular smooth 
muscle cells where it activates guanylate 
cyclase (GC), leading to increased blood flow. 
The balance between NO and various endothe-
lium derived vasoconstrictors and the sympa-
thetic nervous system maintains blood vessel 
tone.
Loss of EDNO would be expected to promote a 
vascular phenotype more prone to vascular dis-
ease. A disturbed synthesis and bioavailability 
of NO might contribute to the onset of demen-
tia by causing impaired endothelial function 
leading vascular disease and loss of direct neu-
roprotective effects [214, 215].
Flow-mediated dilatation: Flow-mediated dila-
tation (FMD) measures the vasodilatation 
response of blood vessels in response to sheer 
stress. A principal mediator of FMD is EDNO. 
Brief ischemia in distal tissue induced by a 
tourniquet results in reactive hyperemia, local 
vasodilatation and increased blood flow in the 
proximal and distal vessels. The increased 
blood flow in the proximal vessel (brachial 
artery) results in increased sheer stress and an 
NO mediated vasodilatation (FMD). Brachial 
artery imaging coupled with reactive hyperemia 
is one of the most common techniques for 
measurement of vascular function [216]. This 
technique involves the occlusion of conduit 
vessels for ~ 5 min causing reactive hyperemia 
of the vascular bed. The subsequent dilatation 
that is expressed as a percentage increase 
from the baseline diameter is mainly depen-
dent on NO activity, with a low percentage indi-
cating poor endothelial function [217].
Laser Doppler flowmetry: Laser Doppler flowm-
etry (LDF) is an inexpensive, non-invasive meth-
od for measurement of skin microcirculation. 
Iontophoresis coupled with LDF makes it pos-
sible to assess the real-time changes of the 
skin blood flow after the administration of dif-
ferent vasoactive substances without systemic 
effects. ACh introduced into the skin by ionto-
phoresis causes endothelium-dependent vaso-
dilatation, which can be compared with the 
endothelium-independent vasodilator effect of 
sodium nitroprusside (SNP), an NO donor [218, 
219]. Sodium nitroprusside reacts with tissue 
sulfhydryl groups under physiologic conditions 
to produce NO directly and thereby stimulate 
SMC relaxation. ACh mediates vasodilatation 
via endothelial-dependent production of NO 
and/or prostanoids with a possible accessory 
role played by endothelium-derived hyperpolar-
izing factor. A Laser Doppler Flowmeter works 
by reading the frequency of the oscillation pro-
duced by the Doppler frequency shift of the red 
blood cells (RBCs) in a peripheral tissue and 
translates the frequency to an intensity oscilla-
tion. The apparatus is composed of a low-pow-
ered laser and probe that takes readings and 
sends results to an analyser. The apparatus 
can penetrate 1-4 mm of non-pigmented tis-
sue. The light emitted and reflected is fed 
through optical fibers to the analyser-recorder. 
The output of the LDF is the flux of RBCs, 
defined as the number of RBCs times their 
velocity, which determines circulation. 
Laser Doppler perfusion imaging: Laser 
Doppler perfusion imaging (LDPI) is based on 
the recording of Doppler shift caused by move-
ments of RBCs in the backscattered light of a 
laser beam that successively scans a certain 
tissue area [220]. A laser Doppler imager gen-
erates a color-coded image of the spatial distri-
bution of tissue perfusion. This allows mea-
surement of tissue blood flow over a set area. 
Iontophoresis of small charged molecules is 
used to assess the skin microcirculation [221].
This technique is increasingly being adopted as 
a clinical measure of endothelial function, sole-
ly in the microcirculation rather than in the 
large conduit arteries. This is useful as the 
microcirculation may well be the initial site for 
endothelial damage [222, 223].
Strain gauge plethysmography: Forearm blood 
flow can be assessed using strain gauge pleth-
ysmography [224]. ACh interacts with endothe-
lial muscarinic receptors and stimulates the 
release of NO. Intra-arterial (brachial) infusion 
of ACh and SNP can be used to assess local 
endothelial-dependent and independent 
responses [225]. The rate of forearm swelling 
during the infusion, measured by strain gauge 
plethysmography, gives an estimate of the 
endothelial function. 
Pulse wave velocity: Pulse wave velocity (PWV) 
is a measure of regional arterial stiffness of the 
arterial area between two measurement sites. 
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PWV is related not only to the elastic modulus 
of the arterial wall (which represents the intrin-
sic stiffness of the wall), but also to the arterial 
geometry and blood density [226]. Although 
structural changes in the vessel wall are a 
major component of arterial stiffness 
(increased collagen and decreased elastin), the 
endothelium also appears to play an important 
dynamic role in arterial stiffness [227]. 
Evidence from both animal [228, 229] and 
human studies [230, 231] suggests that the 
endothelium is an important regulator of arte-
rial stiffness, both functionally and structurally. 
Various interventions that reduce arterial stiff-
ness may also improve endothelial function, 
particularly ACE inhibitors and statins. 
Serum biomarkers: Many serum biomarkers 
have been shown to correlate with endothelial 
function including interleukin-6 (IL-6), tumor-
necrosis factor-α (TNF-α), soluble P-selectin 
and soluble intercellular adhesion molecule-1 
[232]. Plasma nitrite can be used an indicator 
of EDNO generation [233]. In addition, impaired 
tissue plasminogen activator (t-PA) secretion by 
the endothelium has been suggested as a use-
ful measure of endothelial function [234]. The 
sensitivity of t-PA in this setting is apparently 
greater than that for other markers of endothe-
lial dysfunction, including agonist- or flow-medi-
ated vasodilatation, because it is measurable 
in some clinical conditions (e.g., hypertension) 
in which agonist-induced vasodilatation is unal-
tered. CRP is associated with several process-
es involved in endothelial dysfunction, these 
include increasing ET-1 synthesis, down-regu-
lating eNOS, increasing the release of PAI-1 
from ECs, and influencing endothelial progeni-
tor cells [235, 236]. Cellular adhesion mole-
cules (CAMs) are expressed on the surface of 
activated ECs, and increased plasma concen-
trations of soluble CAMs are seen in patients 
with atherosclerosis [237]. 
Plasma asymmetric dimethylarginine (ADMA) is 
increased in patients with vascular disease, as 
well as in patients with risk factors for vascular 
disease [238-240]. In individuals with hyper-
cholesterolemia, plasma ADMA levels provide a 
more accurate indication of endothelial dys-
function than LDL cholesterol levels [240]. 
ADMA inhibits the production of NO in cultured 
ECs and isolated blood vessels [241, 242]. 
Hydrolysis of ADMA by the enzyme dimethyl-
aminohydrolase (DDAH) produces l-citruline 
and methylamine [243]. It has been postulated 
that DDAH regulates NO synthase activity by 
controlling the concentration of ADMA [244]. 
Homocysteine inhibits the activity of endotheli-
al DDAH, causing the accumulation of ADMA 
and the inhibition of NO synthesis [245]. Thus, 
plasma ADMA appears to be a promising indi-
cator of endothelial dysfunction. 
Endothelial function in Alzheimer’s disease: 
available evidence
Search strategy: A search of the published lit-
erature from January 1966 (MEDLINE) and 
from January 1989 (EMBASE) was conducted. 
By way of the advanced search method, the fol-
lowing terms were combined: ‘Alzheimer’s dis-
ease’, ‘cognitive impairment’, and ‘cognitive 
decline’, using the Boolean operator ‘OR’. The 
Boolean operator ‘AND’ was used to link these 
to the terms ‘endothelial dysfunction’, ‘vascular 
reactivity’, ‘flow-mediated dilation’, ‘plethys-
mography’, ‘doppler flowmetry’, and ‘pulse 
wave velocity’. Papers published until February 
2013 were included. Books, abstracts and con-
ference proceedings were excluded.
Eligibility of studies: This review sought publica-
tions with original data on humans suffering 
from dementia of the Alzheimer’s type. Articles 
without proper AD classification were excluded. 
Only articles in English were included, as the 
authors were familiar with these languages. 
Only papers investigating human subjects with-
out a history of cardiovascular events or major 
VRFs were included. Since the endothelium 
possesses different physiologic functions - i.e. 
regulation of vessel tone and expression of 
adhesion molecules - the studies were organ-
ised into subheadings. The references in the 
selected articles were scanned for other rele-
vant articles, using the same criteria. 
Results
By searching MEDLINE and EMBASE 568 
papers were found. Applying the above-men-
tioned criteria yielded a total of 15 articles. The 
main reasons for excluding papers were animal 
models, reviews and vascular or mixed demen-
tia participants. Main findings of the studies for 
each subheading are discussed below. A sum-
mary of results is provided in Tables 1 and 2.
Regulation of vascular tone: Dede et al. evalu-
ated endothelial function in 24 patients with 
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AD-type dementia and 25 age-matched con-
trols using flow-mediated dilatation [246]. 
Significantly lower FMD was found in the AD 
group, which indicated endothelial dysfunction 
(mean FMD: AD group, 3.4±1.7%; control group, 
8.4±3.3%; P<0.001). When the correlation 
between Clinical Dementia Rating (CDR) and 
Mini-Mental State Examination (MMSE) scores 
and FMD values of the total sample (n = 49) 
was examined, FMD had a negative correlation 
with CDR score (r = -0.605, P<0.001) and a 
positive correlation with MMSE score (r = 
0.560, P<0.001). Algotsson et al. measured 
skin vessel reactivity of 15 patients with AD 
and 16 age-matched controls using LDPI [247]. 
Compared to the controls, the skin vessel vaso-
dilatation of the AD group was significantly 
impaired with respect to the reactions to ACh 
and isoprenaline but not SNP in all three tests. 
Khalil et al. measured microvascular respon-
siveness in 75 patients with AD and 168 age-
matched controls using LDF [248]. The ratio of 
ACh response to saline (ratio E/S) was deter-
mined. Mean±SEM of ratios E/S were 8.8±0.9 
for controls and 1.4±0.1 for AD patients, thus 
endothelial dysfunction was present in AD 
patients. Ferenc et al. evaluated flow motion 
pattern in forehead skin using LDF. No signifi-
cant difference in was seen in occurrence of 
forehead vasomotion pattern between patients 
with AD (18%) and age-matched controls (32%) 
[249]. Occlusion (biological zero) values for 
control subjects and AD patients were 5.5±2.2 
and 4.7±0.9 respectively. McGleenon et al. 
measured endothelial function in 9 male and 8 
female patients with AD and 9 male and 12 
female control subjects [250]. The basal FBF 
values were not significantly different for AD 
and controls (mean±(SE), 2.89±1.0 and 
2.81±1.42 d, respectively).
Arterial stiffness: Hanon et al. measured the 
relationship between arterial stiffness and cog-
nitive function in 126 AD patients and 80 age-
matched controls and found significantly higher 
PWV in AD patients (13.3±2.9 m/s) than indi-
viduals without cognitive impairment (11.5±2.0 
m/s; P<0.001) [251]. Dhoat et al. also assessed 
PWV in 16 patients with late onset-AD and 16 
age-matched controls [252]. PWV in the mus-
cular and elastic arteries were not statistically 
different between the two groups.
Expression of serum biomarkers: Borroni et al. 
found a significant difference in thrombomodu-
lin levels (mean SD, control = 6.05±1.9; AD = 
14.9±9.0; p<0.0001) and soluble E-selectin 
(sE-Selectin) (control = 30.3±18.2; AD = 
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50.0±28.5; p<0.001) between 30 patients with 
mild AD and 30 age-matched controls [253]. 
There was an inverse correlation between plas-
matic TM levels and MMSE scores. Gupta et al. 
studied serum markers of coagulation and 
inflammation in patients suffering from demen-
tia [254]. Serum concentrations of vWF, factor 
VII, IL-6, CRP and FDP were significantly higher 
in all three dementia groups (including the 
AD-type group) as compared to controls 
(p<0.001). Zuliani et al. tested endothelial dys-
function in 60 patients with late onset AD by 
measuring plasma levels of E-selectin and vas-
cular cell adhesion molecule 1 (VCAM-1) [245]. 
VCAM-1 levels were significantly increased in 
patients with late onset AD than controls (con-
trol = 562 ng/ml (544-1143); AD = 708 ng/ml 
(471-676); p<0.03) suggesting endothelial 
function is impaired in AD [255]. Järemo et al. 
investigated P-selectin behavior in 23 persons 
diagnosed with moderate AD and 17 healthy 
elders without obvious memory problems 
[256]. Circulating P-selectin was analysed 
using an ELISA technique and flow cytometry 
was used to measure surface-bound P-selectin. 
Soluble P-selectin was augmented in AD (p = 
0.019) but platelet membrane-attached 
P-selectin was not significantly different from 
controls. AD diagnosis was associated with 
less surface-bound P-selectin after provoca-
tion. Significant results were obtained when 74 
μmol/L TRAP-6 (a thrombin-receptor activating 
peptide) was used as a platelet agonist (p = 
0.0008). Selley measured plasma homocyste-
ine, ADMA, and NO (nitrite and nitrate) concen-
trations in patients with AD and healthy con-
trols [257]. AD patients showed higher plasma 
ADMA (AD = 1.84±0.08; control = 1.41±0.05 
μmol/L, p<0.0001) and homocysteine concen-
trations, and lower NO concentrations, than 
controls. Abe et al. measured ADMA concentra-
tions in the cerebrospinal fluid in AD patients 
and healthy controls [258]. AD patients had sig-
nificantly lower ADMA concentrations in the 
cerebrospinal fluid (AD = 0.014±0.006; con-
trols = 0.027±0.008 μmol/L, p = 0.0001). 
There was a significant correlation between 
lower cerebrospinal concentrations of ADMA 
and lower MMSE in patients with AD (r = 0.58, 
p<0.05). Mulder et al. also measured ADMA 
concentrations in the cerebrospinal fluid in AD 
patients and healthy controls [259]. Unlike the 
study by Abe et al. no significant differences 
were observed between the 2 groups (AD = 
0.066±0.012; control = 0.065±0.010 μmol/L; 
p = 0.91) [258]. Finally, Arlt et al. measured 
ADMA concentrations both in plasma and in 
the cerebrospinal fluid in AD patients and 
healthy controls [260]. AD patients had higher 
plasma ADMA concentrations (AD = 0.65±0.11; 
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control = 0.54±0.11 μmol/L; p<0.001), but 
lower cerebrospinal fluid ADMA concentrations 
(AD = 0.15±0.03; control = 0.22±0.12 μmol/L; 
P = 0.022), in comparison to healthy controls. 
However, these differences were not 
significant.
Discussion
The evidence reviewed suggests vascular 
involvement plays a role in the pathogenesis of 
AD. Morphological changes in the endothelium 
and the VBM, as well as diminished endothelial 
repair capacity have been recorded in AD [117]. 
Vascular abnormalities may be attributed to 
vascular disorders that frequently develop and 
progress with increasing age [57]. These vascu-
lar alterations probably facilitate several fac-
tors that are potentially neurotoxic. In particu-
lar, amyloid has received a great amount of 
interest as it is overproduced in AD and has 
been found to be neurotoxic [40, 41]. In ageing, 
it is possible that vascular dysfunction may 
occur early on or even precede the pathological 
features of AD. As AD is a neurodegenerative 
disorder in which amyloid accumulation is 
believed a key event, it may be that an associa-
tion exists between vascular changes and amy-
loid production.
Aβ may be produced by endothelial, neuronal 
and glial cells [187]. It has been postulated that 
Aβ deposition stimulates the production of 
ROS, which in turn cause vascular oxidative 
stress and cerebrovascular dysfunction [261]. 
In vitro findings are supported by studies indi-
cating that cerebral ischemia causes stress-
induced amyloid deposition in highly vascular-
ized cortical brain regions [137, 139]. These 
theories suggesting a possible synergistic rela-
tionship between Aβ deposition and vascular 
dysfunction may provide an explanation for 
endothelial dysfunction in AD.
In our systematic search, we found that studies 
investigating a possible relationship between 
endothelial dysfunction and AD in vivo were lim-
ited. The results of published studies show evi-
dence of endothelial dysfunction in AD except 
for the studies by McGleenon et al., Malt et al., 
Dhoat et al., Arlt et al. and Mulder et al.. 
Although the measurement of endothelial dys-
function was quite diverse, elevated levels of 
serum biomarkers suggestive of endothelial 
dysfunction (TM, vWF, ADMA etc.), abnormal 
values of FMD and blood flow abnormalities 
assessed using Doppler shift were all associ-
ated with AD. These findings suggest that, inde-
pendent of any other VRFs, endothelial function 
is present in AD, which could indicate a system-
ic element in AD pathology.
Another hypothesis is that only cerebral vascu-
lar function is compromised in AD [149]. The 
techniques reviewed in this study are all limited 
in their assessment of the peripheral circula-
tion. However, there is currently no effective 
method of measuring endothelial function in 
the cerebral circulation. Moreover, McGleenon 
et al. found that cerebral vessels and peripher-
al vessels show similar responses to ACh infu-
sion [250]. Nevertheless, the argument remains 
that whilst the peripheral circulation remains 
functional the cerebral circulation may be com-
promised in AD.
In vivo studies of endothelial function are 
fraught with difficulty and currently no gold 
standard exists. Many measurements that are 
purported to measure endothelial function 
actually measure “vascular reactivity.” Although 
many researchers consider FMD the gold stan-
dard for clinical research [207], it is not without 
its limitations [262]. FMD provides little mecha-
nistic data and structural alterations of blood 
vessels in vascular disease which affect their 
ability to dilate may affect results. Moreover, 
lack of standardisation and variations in posi-
tioning of the arm cuffs and measurement of 
vessel diameter make comparing study results 
challenging [263]. Despite the similarities in 
vascular responses between the skin microcir-
culation and larger arteries, whether skin 
blood-flow studies (Doppler imaging and 
Doppler flowmetry) are indicative of other vas-
cular beds is unclear and requires further 
research [264]. Strain gauge plethysmography 
is an invasive technique involving cannulation 
of the brachial artery, which is not without some 
risk. Thus, this is a specialist technique that is 
not suitable for widespread use. Further stud-
ies are required to fully comprehend the link 
between endothelial function and arterial stiff-
ness. Although most studies suggest that the 
endothelium regulate stiffness, impaired elas-
tic function itself might have adverse effects on 
endothelial function, and future work needs to 
address this issue [265]. Finally, the use of 
serum biomarkers to measure vascular dis-
ease or prognosis is still at an early stage in 
development. 
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The studies published so far cannot establish 
whether endothelial dysfunction in AD is caus-
ative or coincidental. It would be ideal to collect 
measurements before symptoms of AD occur in 
a population-based design. However, this would 
require a very large study population. 
Furthermore, none of the markers described 
are brain-specific endothelial markers and 
endothelial function may vary across vascular 
beds [264, 266].
A major limitation in the literature on AD and 
endothelial dysfunction is the relative paucity 
of studies and small number of subjects in 
each study. A much larger population is neces-
sary to prove any clinical significance. It may be 
difficult to recruit volunteers with AD for inva-
sive studies due to volunteer frailty and lack of 
independent decision-making capacity in these 
individuals. Patients with AD often have vascu-
lar risk factors (VRFs) and it is challenging to 
find subjects without accompanying vascular 
conditions. However, only patients without 
existing VRFs were included in these investiga-
tions. Whilst this eliminates the possibility of 
the endothelial dysfunction of subjects being 
caused by conditions other than AD, it is well 
known that a high proportion of the AD popula-
tion has vascular conditions, which may be 
associated with the pathogenesis of AD [57, 
267]. The evidence, therefore, may not be gen-
eralisable to the AD population as a whole. 
Future research investigating the relationship 
between AD and endothelial dysfunction should 
include subjects with and without VRFs to give 
a more accurate representation of the general 
AD population.
A final limitation of the reviewed studies was 
that they focused on serum markers of endo-
thelial dysfunction (e.g. vWF) or on function 
assessment (e.g. FMD). For the future, it would 
be ideal to combine both methods to provide as 
robust an evidence base as possible.
Although this review was not a full systematic 
review, it aimed to provide a thorough analysis 
of evidence of endothelial dysfunction in AD. 
Strict selection criteria were employed with the 
aim to provide enough information to allow 
repeatability and enhance the validity of find-
ings. However, it is possible that some of the 
published literature was not included. Whilst 
the studies reviewed suggest endothelial dys-
function may be present in AD, more research 
is required to prove this link. 
Conclusion 
There is conflicting evidence regarding the 
pathogenesis of AD. The vascular hypothesis 
challenges the long established neuron-centric 
view of AD. It is likely that AD has both neurode-
generative and vascular elements. Based on 
our findings, we suggest endothelial dysfunc-
tion may play a role in AD pathogenesis. More 
basic and clinical research on the vascular fea-
tures of AD is required. Further study may have 
implications for therapeutic intervention with 
the potential to reverse or prevent endothelial 
dysfunction and relieve or prevent the symp-
toms of AD. 
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